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Four endemic human coronaviruses (HCoVs) are commonly associated with acute respiratory 
infection in humans. B cell responses to these “common cold” viruses remain incompletely 
understood. Here we report a comprehensive analysis of CoV-specific antibody repertoires in 
231 children and 1168 adults using phage-immunoprecipitation sequencing. Seroprevalence 
of antibodies to endemic HCoVs ranged between ~4 and 27% depending on the species and 
cohort. We identified at least 136 novel linear B cell epitopes. Antibody repertoires against 
endemic HCoVs were qualitatively different between children and adults in that anti-HCoV 
IgG specificities more frequently found among children targeted functionally important and 
structurally conserved regions of the spike, nucleocapsid and matrix proteins. Moreover, 
antibody specificities targeting the highly conserved fusion peptide region and S2’ cleavage 
site of the spike protein were broadly cross-reactive with peptides of epidemic human and 
non-human coronaviruses. In contrast, an acidic tandem repeat in the N-terminal region of 
the Nsp3 subdomain of the HCoV-HKU1 polyprotein was the predominant target of antibody 
responses in adult donors. Our findings shed light on the dominant species-specific and pan-
CoV target sites of human antibody responses to coronavirus infection, thereby providing 
important insights for the development of prophylactic or therapeutic monoclonal antibodies 
and vaccine design.       
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Introduction 
Four endemic human-tropic coronaviruses (HCoVs) are commonly associated with respiratory 
illness in humans, namely HCoV-229E, -NL63, -OC43, and -HKU1 (1-4). Clinical outcomes of 
acute infection with these HCoVs range from mild upper respiratory tract infections in most 
patients, to viral bronchiolitis and pneumonia in rare patients, the latter requiring 
hospitalization (5). The ratio of more severe versus mild outcomes of acute infection with 
endemic HCoVs is largely comparable to that of other “common cold” viruses, such as human 
respiratory syncytial virus (HRSV), human rhinoviruses (HRVs), human adenoviruses (HAdVs), 
and human parainfluenza viruses (HPIVs), albeit with differences in seasonality and 
prevalence of the viruses depending on the species (5-7). In addition to the four endemic 
HCoV, three human-tropic epidemic coronaviruses (CoVs) have emerged over the last two 
decades, namely Severe Acute Respiratory Syndrome-associated CoV (SARS-CoV) (8), Middle 
East Respiratory Syndrome-associated coronavirus (MERS-CoV) (9), and SARS-CoV-2 (10), the 
etiological agent of Coronavirus Disease 2019 (COVID-19) which has now reached pandemic 
proportions (11). Similar to endemic HCoVs, infection of humans with epidemic CoVs is 
associated with a wide range of outcomes but leads more frequently to severe clinical 
manifestations such as acute respiratory distress syndrome (ARDS) (12-14). Phylogenetic 
analyses suggest that, similar to these epidemic CoVs, all endemic HCoVs are of zoonotic 
origin and their possible ancestors share similar natural animal reservoirs and intermediate 
hosts (6). HCoV-229E may have been transferred from dromedary camels, similar to MERS-
CoV, while HCoV-OC43 is thought to have emerged more recently from ancestors in domestic 
animals such as cattle or swine in the context of a pandemic at the end of the 19th century 
(6, 15). 
 
The wide variability in transmissibility and clinical manifestations of infections by endemic 
and epidemic CoVs among humans remains poorly understood. On the population level, the 
case-fatality rate is highest for MERS (~34 - 37%) and several risk factors are associated with 
progression to ARDS in MERS, SARS and COVID-19 cases, including old age (i.e., people aged 
65 years or over), diabetes mellitus, hypertension, cancer, renal and lung disease, and co-
infections (12, 16). Nonetheless, even MERS-CoV infection among humans can run a 
completely asymptomatic course in some cases, particularly among children (17-19). There is 
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evidence that children are generally less susceptible to infection with epidemic CoVs and once 
infected, they are less likely to experience severe outcomes compared to adults, although this 
important association and the underlying reasons remain poorly understood (12, 18, 20, 21). 
Importantly, it remains unclear to what extent pre-existing immunity from past infections 
with endemic HCoVs provides some degree of cross-protection and affects clinical outcomes 
of infection with the epidemic SARS-CoV-2 or MERS-CoV. Our overall understanding of the 
immunity induced by natural infection with endemic HCoVs remains very limited. Serological 
studies have shown some degree of cross-reactive antibodies in patients with past CoV 
infections but many of these studies were limited in sample size and often focused on specific 
viral antigens only (22-25). Depending on their binding affinity and specificities, such cross-
reactive antibodies could either have no effect on clinical outcomes, may provide protection 
from severe disease to some degree, or may lead to antibody-dependent enhancement of 
disease—the latter can be a major obstacle in vaccine development (26). Interestingly, two 
recent studies from independent groups have shown that a considerable proportion of 
individuals without a history of SARS-CoV-2 infection have SARS-CoV-2-reactive T cells, which 
suggests that cross-reactive T cell subsets originating from past infections by endemic HCoVs 
may play a role in the clinical course of infection with the phylogenetically related epidemic 
CoVs (27, 28). A systematic assessment to elucidate the immunodominant B cell antigen 
determinants of endemic HCoVs has not been done. We hypothesized that a fraction of the 
general population also have antibodies generated during past encounters with ‘common 
cold’ coronaviruses that cross-react with proteins of epidemic CoVs. This may affect the 
dynamics of sporadic MERS outbreaks that mostly occur in the Middle East, and the current 
COVID-19 pandemic.  
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Results 
To gain a deeper insight into human antibody responses to endemic HCoVs, we performed 
phage-immunoprecipitation sequencing (PhIP-Seq) (29, 30) on previously collected serum or 
plasma samples obtained from a total of 1431 human subjects from three different cohorts. 
These included i) healthy male adult blood donors (ABD) with diverse ethnic background and 
nationality (Supplementary Figure S1A); ii) adult male and female participants of a national 
cohort study—the Qatar Biobank (QBB) (31)—representing the general population 
(Supplementary Figure S1B); and iii) pediatric outpatients and inpatients who were tested for 
metabolic conditions unrelated to infection, chronic disease or cancer (Methods and 
Supplementary Figure S1C). The samples were collected prior to the current COVID-19 
outbreak (Methods). In brief, PhIP-Seq allowed us to obtain comprehensive antiviral antibody 
repertoires across individuals in our three human cohorts using phage display of 
oligonucleotide-encoded peptidomes, followed by immunoprecipitation and massive parallel 
sequencing (29, 30). The VirScan phage library used for PhIP-Seq in the present study 
comprised peptides derived from viral proteins—each represented by peptide tiles of up to 
56 amino acids in length that overlap by 28 amino acids—which collectively encompass the 
proteomes of a large number of viral species, including HCoV-229E, -NL63, -HKU1 and -OC43 
(29, 30). Proteins of endemic HCoVs which were represented in the VirScan phage library 
included the ORF1ab replicase polyprotein (pp1ab), the spike glycoprotein (S), the matrix 
glycoprotein (M), the nucleocapsid protein (N) and gene products of the species- and strain-
specific open reading frames (ORFs) encoded in the 3’ region of the viral genomes 
(Supplementary Table S1). Of note, we utilized an expanded version of the VirScan phage 
library (32, 33), which also encompassed peptides from a number of proteins of human 
epidemic and non-human CoV isolates, including MERS-CoV, SARS-CoV, as well as bat, bovine, 
porcine and feline isolates belonging to the alpha- and betacoronavirus genera, albeit with 
varying coverage of the viral peptidomes owing to the limitation in available sequence data 
for the latter isolates in UniProt (Supplementary Table S1). SARS-CoV-2 peptides were not 
included in the VirScan phage library used in our study. 
 
We were able to obtain antibody repertoires for a total of 1399 individuals from the human 
cohorts described above (Supplementary Table S2). Using stringent filter criteria (Methods), 
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we identified a total of 417 out of 2498 peptides and potential antigens from endemic HCoVs 
with our screen that were significantly enriched in at least three of all 1399 analyzed 
individuals. A total of 103 peptides from endemic HCoV were enriched in ³ 1% of the samples 
and therefore considered to contain potentially immunodominant regions (Supplementary 
Table S3). Only 33 of the 417 peptides enriched in at least three samples shared linear 
sequence homology with epitopes that have previously been reported (34) (Supplementary 
Figure S2). To estimate number of newly identified linear B cell epitopes, we assigned each 
CoV-derived peptide to clusters of peptides that share  ³ 7 amino acids linear sequence 
identity—the estimated size of a linear B cell epitope (Methods). The enriched peptides could 
be assigned to 149 clusters for which at least 2 peptides share linear sequence identity of ³ 7 
amino acids (Supplementary Tables S3 and S4). Only 13 clusters also shared  ³ 7 amino acids 
linear sequence identity with known linear B cell epitopes. Consequently, we have identified 
a minimum of 136 new linear epitopes, including 25 new immunodominant linear B cell 
epitopes [i.e. B cell epitopes targeted in at least ³ 1% of all individuals and not already 
reported in the Immune Epitope Database (IEDB) (www.iedb.org) (34) (Supplementary Table 
S3)].  
 
Next we assessed the seroprevalence of HCoV-229E, -NL63, -HKU1 and -OC43 in the three 
cohorts separately. To do so, we imputed species score values as described earlier (30, 32, 
35) by counting the significantly enriched peptides for a given HCoV species that share less 
than 7 amino acids linear sequence identity. We considered an individual seropositive for any 
of the endemic HCoVs if the number of non-homologous peptides enriched in a given sample 
met our previously established species-specific cut-off value (Methods). Seroprevalence for 
endemic HCoVs ranged from ~4% to ~27%, depending on the species and cohort (Figure 1A), 
and also varied when stratifying the subjects by age group or gender (Supplementary Table 
S5). Interestingly, we found a marginal but significant negative association between age and 
seroprevalence of HCoV-OC43 (b = -0.175) and -NL63 (b = -0.315), as well as a marginal 
positive association between male gender and seroprevalence for any of the endemic HCoVs 
(b  £ 0.2) (Figure 1B). The species score values (i.e. the antibody repertoire breadth for each 
HCoV species) did not differ substantially between seropositive individuals of our 3 cohorts 
(Supplementary Figure S3). However, principal component analysis revealed considerable 
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qualitative differences in the antibody repertoires between our cohorts and in particular 
between pediatric and adult subjects (Figure 2A). For comparison, we also performed the 
same analysis on enriched peptides from other common respiratory viruses, including HRSV, 
HRV A, HRV B and influenza B virus. As expected, seroprevalence was considerably higher 
(68% to 99%) for HRSV, HRV A and HRV B, and somewhat higher (29% to 47%) for influenza B 
virus (Supplementary Figure S4A). However, contrary to antiviral antibody responses to 
endemic HCoVs, we did not find considerable variance in the antibody repertoires to other 
respiratory viruses when comparing age groups and cohorts (Supplementary Figure S4B). We 
also analyzed the enriched antigenic peptides for each endemic HCoV species separately and 
found that most variance in the antibody repertoires between cohorts and age groups were 
attributable to past infections with HCoV-HKU1 and -229E (Supplementary Figure S4C). To 
determine the antibody specificities responsible for most of the variance in the antiviral 
response to endemic HCoVs between adults and children (i.e. to identify those peptides that 
were significantly more or less frequently enriched when comparing adult and pediatric 
donors), we applied Fisher's exact test and computed log odds ratios (lod) for each of the 
significantly enriched peptides. We found that antibody specificities in samples of pediatric 
study subjects predominantly targeted different antigenic regions in the S protein (mean lod 
= 3.35, SD = 2.12), the N protein (mean lod = 2.21, SD = 1.41) and diverse antigenic sites in 
pp1ab, whereas peptides encoding a single linear B cell epitope of pp1ab (cluster 22) 
appeared to be the predominant target of IgG antibodies among adult donors (mean lod = -
4.7, SD = 1.16) (Figure 2B and Table 1).  
 
Intriguingly, multiple sequence alignments of frequently enriched peptides with the full-
length proteins of various CoVs revealed that antibody specificities predominantly found in 
pediatric study subjects target immunodominant epitopes that encode functionally important 
and highly conserved regions of the structural proteins. These included regions in the S1 
subunit of the S protein which are important for receptor binding (36-39), as well as the 
regions resembling the proteolytic cleavage sites and fusion peptide of the S2 subunit (Figure 
3 and Supplementary Figure S6). Of note, the immunodominant region spanning the furin-
like S2’ cleavage site in the S2 subunit resembles one of the most conserved regions of the S 
protein, both in amino acid sequence (R¯SA[I/L]ED[I/L]LF) (Figure 3E) and in protein structure, 
as it forms an accessible alpha-helix within the fusion peptide region (Supplementary Figure 
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S6) (40). Moreover, we identified potential antibody binding sites in the N-terminal RNA 
binding domain, serine/arginine-rich region and in the C-terminal dimerization domain of the 
N protein (Figures 4A and 4B). Although the predicted antibody binding sites in the N-terminal 
RNA-binding domain and the C-terminal dimerization domain of the N protein appeared to 
be less conserved between different species in the primary amino acid sequence (Figure 4C 
and 4D), both domains are structurally conserved in the regions that we found to be 
immunodominant (Supplementary Figure S7). We also found that antibodies in children 
targeted more frequently the C-terminal domain of the M protein (Supplementary Figure S5C 
and Table 1) and the small accessory ORF8 protein (also known as N2) of HCoV-HKU1 (Table 
1). Although ORF8 and N share the same coding sequence in the viral RNA genome, the 
reading frame is different and the amino acid sequences not homologous. On the contrary, 
antibody specificities predominantly found in adults primarily targeted a region of the pp1ab 
that is specific to HCoV-HKU1 and contains an acidic tandem repeat (NDDE[D/H]VVTGD) 
which is located upstream of the papain-like protease 1 domain (Supplementary Figure S5D).  
 
Given the high degree of sequence conservation among some of the immunodominant 
regions in proteins of endemic HCoVs we have identified, we also explored the extent to 
which antibody specificities to these regions cross-react with peptides from epidemic CoVs 
and non-human CoV isolates. For this purpose, we assessed the enrichment of peptides 
derived from SARS-CoV, MERS-CoV as well as bovine, porcine, bat and feline CoV isolates 
(Supplementary Table S1) applying the same approach and stringent filter criteria as 
described above for peptides of endemic HCoVs. Indeed, we identified several S protein- and 
N protein-derived peptides from epidemic CoVs or non-human isolates that were significantly 
enriched in our PhIP-Seq assay, which share sequence similarity with peptides from HCoVs 
(Figure 5). As expected based on the results from multiple sequence alignments described 
above, antibody specificities targeting the highly conserved amino acid motif 
(RSA[I/L]ED[I/L]LF) spanning the furin-like S2’ cleavage site of the S protein were broadly 
cross-reactive to several orthologous peptides from MERS-CoV, SARS-CoV and non-human 
CoV isolates (Figure 5A). Cross-reactivity of antibodies targeting other functionally important 
but less conserved regions of the S protein also appeared to be more restricted (Figure 5A). 
Antibody specificities targeting the N protein also showed considerable cross-reactivity with 
peptides from MERS-CoV, SARS-CoV and non-human CoV isolates. However, the latter cross-
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reactive antibodies mainly targeted regions rich in serine and arginine residues, with low-
complexity sequences and very limited structural conservation, particularly an intrinsically 
disordered region (IDR) at the N terminus of the N protein (Figure 5B and Supplementary 
Figure S9) that lacks a tertiary structure (41). We also detected cross-reactive antibodies 
targeting the serine- and arginine-rich linker region of the N protein; however, cross-reactivity 
to this region was largely restricted to peptides derived from non-human CoV isolates of 
domestic animals (Figure 5B) which are more closely related to HCoV-OC43 (6).  
 
Finally, we assessed plasma samples of a previously healthy 49-year-old female adult patient 
who suffered from severe ARDS from SARS-CoV-2 infection, requiring prolonged 
hospitalization and intensive care. A first sample was obtained 25 days after onset of 
symptoms and 18 days after ICU admission. A second sample was obtained one month later, 
one week after discharge. We compared the antibody profiles at both time points to samples 
obtained from uninfected family members of the patient, as well as an age- and gender-
matched unrelated control. In agreement with what we found in some subjects with a history 
of endemic HCoV infection, the patient with severe COVID-19 had detectable antibodies that 
cross-reacted with peptides from SARS-CoV and non-human CoVs encoding the furin-like S2’ 
cleavage site and heptad repeat 2 region of the S protein, peptides from the C-terminal region 
of the HCoV-HKU1 N protein downstream of the dimerization domain, as well as two antigenic 
sites of the MERS-CoV pp1a (Supplementary Figure S8). We confirmed these findings by 
analyzing additional plasma samples obtained at a single time point from six additional male 
COVID-19 patients between 5 and 12 days after onset of symptoms (Supplementary Table 
S6). Indeed, several of the cross-reactive anti-S, anti-N and anti-pp1a antibodies that we had 
found in the female COVID-19 patient with severe ARDS were also detectable in male subjects 
and earlier in the course of infection (Supplementary Table S7).   
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Discussion 
Our comprehensive and systematic screen for antiviral antibody repertoires across individuals 
in three human cohorts revealed a large number of peptides with novel linear B cell epitopes 
in several proteins of endemic HCoVs. This is not surprising given that epidemic CoVs, and in 
particular SARS-CoV, have been the primary focus of previous immunological and epitope 
screening studies  (34, 42). Information about the targets of immune responses to CoVs across 
different species provides a valuable resource for the prediction of candidate targets of newly 
emerging CoVs, as recently shown by Grifoni et al. (42). The authors were able to identify a 
priori, several specific regions of the S, M and N proteins of SARS-CoV-2 on the basis of 
sequence homology to the SARS-CoV virus which are orthologous to several of the 
immunodominant regions of endemic HCoVs we identified. We detected antibodies against 
the structural S, N, M and ORF8 proteins, as well as the non-structural pp1ab polyprotein of 
HCoVs; the latter resembling the precursor for the large viral replicase complex (43). 
Interestingly, in another independent study, Grifoni et al. (28) recently reported similarly 
broad T cell responses in COVID-19 patients by employing an analogous screen for T cell 
epitopes of SARS-CoV-2 proteins using peptide ‘‘megapools’’ in combination with ex vivo T 
cell assays.     
 
Surprisingly, circulating IgG antibodies in children appear to be differentially targeting 
structural and non-structural proteins of HCoVs in comparison to adults (Figure 2). Whereas 
antibody specificities more frequently found in samples of pediatric subjects targeted 
structural proteins such as the S, N and M proteins, in adult donors, a region of the non-
structural polyprotein pp1ab containing an acidic tandem repeat (NDDE[D/H]VVTGD) in 
HCoV-HKU1 appeared to be the predominant target of IgG antibodies. The latter polyprotein 
is post-translationally processed into up to 16 subunits that form a large viral replicase 
complex; however, the function of the acidic tandem repeat and its role in pathogenesis 
remains unknown (43). This qualitative difference in the antibody repertoires of adult versus 
pediatric subjects appeared to be a specific characteristic of natural HCoV infection, as we did 
not find the same degree of variance in the antibody repertoires specific to other common 
respiratory viruses when comparing our cohorts and different age groups (Supplementary 
Figure S4). We speculate that the qualitative differences in antibody repertoires of adult 
 12 
versus children reflect a higher frequency and/or more recent exposures of children to 
seasonal coronaviruses than adults, coupled with the rapid decay of circulating anti-CoV 
antibodies that target the structural proteins of the virions. Further studies will be needed to 
fully understand the dynamics of antibody responses to endemic HCoVs.  
 
Evidence for the transient and dynamic nature of humoral immunity to endemic HCoVs has 
been provided by number of human serological studies, although many of them were 
conducted with only a limited number of subjects, or only for selected species, and a variety 
of antibody detection methods were used that are not readily comparable (44-51). 
Nevertheless, evidence suggests that a sizable proportion of children experience primary 
infection with endemic HCoVs during their first year of life and nearly all children have 
encountered at least one of the endemic HCoVs before two years of age, indicating that first 
exposure to endemic HCoVs occurs very early in life, similar to other common respiratory 
viruses such as HRSV or HRVs (45, 49, 50). However, reported seroprevalence rates in older 
children and adults vary greatly depending on a variety of factors, including age and viral 
species. There is a general trend indicating that humoral immunity from primary infection 
with endemic HCoVs wanes quickly and that antibodies detected in older children and adults 
are rather a consequence of more recent re-infections (44-48). We estimated the 
seroprevalence of antibodies to endemic HCoVs to range between ~4% and ~27% depending 
on the species and cohort (Figure 1A). Given that endemic HCoV infections are common and 
usually acquired during early childhood (45, 46, 49, 50), it is likely that not only the adult 
subjects, but also many (if not all) of the children aged 7 to 15 years that were assessed in our 
study, have already experienced multiple infections with endemic HCoVs in their lifetime. 
Therefore, our estimated seroprevalence rates likely reflect the complex dynamics between 
rates of (re-)infection and waning humoral immunity over time. In agreement with this 
notion, age was negatively associated with seroprevalence in our study, suggesting that the 
duration of immunity in response to natural infection with endemic HCoVs and/or rates of re-
infection reduce with increasing age. The dynamics of humoral immunity from past CoV 
infections is best described in studies of MERS and SARS patients. Although limited in sample 
size, these studies have shown that antibody titers in all previously infected individuals 
decline relatively quickly to minimal detectable levels over a period of 2 to 3 years and that 
patients who suffered from more severe disease had higher and longer-lasting total binding 
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antibody titers and neutralizing titers (51). There is also evidence that symptomatic COVID-
19 patients mount robust antibody responses that wane very quickly over a period of 6 
months (52). However, the same study suggeted that SARS-CoV-2-specific memory B cells 
may be sustained over a longer period of time (52). Indeed, most acute virus infections induce 
some level of protective and long-term immunity, albeit through a variety of mechanisms that 
are not necessarily the same for each pathogen and may even differ between hosts due to a 
variety of factors, including simultaneous viral coinfection (53, 54). Interestingly, a recent 
study by Weisberg et. al. (55) demonstrated distinct antibody responses to SARS-CoV-2 in 
children and adults, which was found to be independent of the clinical outcomes and severity 
of infection. Even children with mild disease generated antibody responses against SARS-CoV-
2 with reduced breadth and surprisingly also reduced neutralizing activity compared to adults. 
It is therefore also possible that children experience an altogether distinct course of infection 
compared to adults, and consequently differ in their serological responses, perhaps due to 
differences in expression levels of the viral receptor, angiotensin-converting enzyme 2 (ACE2), 
in airway epithelial cells (55). This requires further research. We also found a marginal but 
significant positive association between seroprevalence of endemic HCoVs and male gender, 
which is consistent with an earlier report by Gaunt et al. (5). 
 
Despite the variable degree of sequence conservation between different CoV species, the 
results of our systematic antibody screen highlight that the structural proteins of the virions 
share common antigenic sites. Indeed, several of the immunodominant regions we have 
identified experimentally in the structural proteins of endemic HCoVs are orthologous to the 
regions thought to be immunodominant targets for immune responses to SARS-CoV-2 (42) 
(Supplementary Figure S8), including two linear epitopes on the SARS-CoV-2 S protein that 
elicit potent neutralizing antibodies in COVID-19 patients (56). Importantly, antigenic regions 
that we found to be immunodominant in our study (i.e. enriched in ³ 1% of all samples), as 
well as those corresponding to peptides for which enrichment was strongly and significantly 
associated with pediatric subjects (OR ³ 2; P value £ 0.005, Fisher’s exact test), mapped to 
functionally important regions of the structural CoV proteins. These included regions for 
receptor binding and the proteolytic cleavage sites of the S protein, as well as the N-terminal 
RNA-binding and C-terminal dimerization domains of the N protein, which have been shown 
to be critical for virus attachment and entry, cell-to-cell fusion and virus replication, 
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respectively (41, 57-61).  The region of the S1 subunit responsible for receptor binding differs 
considerably between CoV species, which utilize different domains and host cell receptors, 
and consequently differ in their tissue tropism (37-40, 46, 62). However, the S2 subunit 
resembling the fusion machinery is more conserved, both structurally and in amino acid 
sequence (38, 63) (Supplementary Figure S6). Indeed, we identified an immunodominant and 
highly conserved linear epitope immediately downstream of the furin-like S2’ cleavage site of 
the S protein (R¯SA[I/L]ED[I/L]LF) that likely resembles the fusion peptide, although its 
precise location has been disputed (64). The same antigenic site has recently been found on 
the SARS-CoV-2 S protein to elicit neutralizing antibodies in COVID-19 patients (56). The high 
degree of amino acid sequence and conformational conservation of the alpha-helical region 
immediately adjacent to the S2’ cleavage site (Figures 3E and Supplementary Figure S6A) 
likely explains why antibodies targeting this region also cross-reacted with orthologous 
peptides of related CoVs in our study, including that of MERS-CoV, SARS-CoV and non-human 
isolates, further supporting our overall hypothesis and the important role of this particular 
region as a pan-CoV target site (40, 56). It is therefore tempting to speculate that at least in 
some individuals, past infections with endemic HCoVs have elicited cross-reactive antibodies 
and/or led to the generation of longer-lived memory B cells with specific reactivity to this 
linear epitope, which may provide cross-protection against MERS or COVID-19. This may be 
the case particularly among children which are generally less likely to experience severe 
disease outcomes from infection with epidemic CoVs (17-19, 21). In this context, it is 
important to highlight that antiviral antibodies can have a variety of protective effector 
functions that operate through different mechanisms. The underlying mechanisms for 
antibody-dependent neutralization of enveloped viruses (i.e., the inhibition of virus 
replication by blocking viral entry into the host cell) include the competitive binding of high-
affinity antibodies—via their variable fragment antigen-binding (Fab) regions—to specific 
regions within the viral attachment and fusion protein(s) that are also critical for the 
interaction with the host cell receptor(s) or activating host proteases (56). Neutralizing 
antibodies may also interfere with the fusion machinery, which undergoes profound 
activating conformational changes upon viral attachment to overcome the repulsive force 
between the viral envelope and host cell membrane bilayers (38). Additional antibody 
effector functions are Fc-mediated, require the participation of additional host immune 
components and are not necessarily restricted to antibodies targeting the viral attachment 
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and fusion protein(s). This includes complement-dependent cytotoxicity, as well as 
enhancement of antibody-dependent cell-mediated cytotoxicity and/or phagocytosis (65, 
66). The specific effector functions and mechanisms that are primarily responsible for the 
generally milder clinical outcome among children when infected with epidemic CoVs remain 
elusive (55). 
 
Broadly cross-reactive antibody responses are also known for other enveloped RNA viruses, 
which may positively or negatively affect subsequent infection or vaccination. Flaviviruses for 
example, are antigenically related and broadly flavivirus cross-reactive antibodies from 
previous yellow fever vaccination has been shown to impair and modulate immune responses 
to tick-borne encephalitis vaccination (67). Similarly, immune history has been shown to 
profoundly affect protective B cell responses to influenza (68). Since we detected pan-CoV 
cross-reactive antibodies less frequently in plasma samples from adult donors, our results 
argue against a strong therapeutic benefit of intravenous immunoglobulin products to control 
the spread of COVID-19 disease (69). In this context, it should be noted that large-scale 
antibody screening by PhIP-Seq may frequently fail to detect conformational and post-
translationally modified B cell epitopes (29). Nontheless, we found anti-CoV antibodies in 
plasma of a COVID-19 patient after prolonged hospitalization and intensive care that targeted 
largely the same structurally conserved and functionally important regions of the viral N and 
S proteins (Supplementary Figure S8) as those that we detected in a sizable proportion of 
children, including antibodies binding to the highly conserved motif and furin-like S2’ cleavage 
site (R¯SA[I/L]ED[I/L]LF), which provides further evidence for the clinical benefit of using 
convalescent plasma for the prevention and treatment of COVID-19 (65, 70, 71).  
 
Our findings may also have important implications for the development of prophylactic or 
therapeutic monoclonal antibodies and vaccine design, such as in the context of COVID-19 
(42, 72). The design of immunogens for next generation vaccines and the development of 
monoclonal antibody therapies requires a detailed understanding of the immunogen 
structure and antibody recognition sites. Endemic HCoVs share common features with 
epidemic human-tropic CoVs and other enveloped, human-pathogenic viruses, many of which 
remain obscured by current amino acid sequence alignment tools due to the rapid evolution 
of viruses. The attachment and fusion protein(s) of enveloped viruses for example are key 
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immunogens that share common structural features and employ a similar mechanism for 
catalyzing membrane fusion between the viral envelope and host cell. The coronavirus S 
protein belongs to the so-called class I viral fusion proteins, along with the influenza 
hemagglutinin (HA) protein, the hRSV fusion (F) protein, the Ebola virus glycoprotein (GP) and 
the HIV-1 envelope (Env) protein. An important characteristic of these proteins is their 
conformational dynamics, which is critical for their function, but this has also proven to be a 
major challenge for structural analyses. Studies of HIV Env, hRSV F and the fusion proteins of 
other enveloped viruses have highlighted that potent neutralizing antibodies primarily 
recognize the protein’s pre-fusion form in the closed confirmation and that it is important to 
stabilize this form for structural analysis (in some cases in complex with bound antibodies), 
as well as for immunogen design to avoid undesirable antibody responses (38).        
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Methods 
Study design and samples. We performed a retrospective analysis of deidentified or coded 
plasma and serum samples collected from three different human cohorts, namely: i) 400 
healthy male adult blood donors (ABD) of a blood bank in Qatar with diverse ethnic 
background and nationality (Supplementary Figure S1A); ii) 800 adult male and female Qatari 
nationals and long-term residents of Qatar who are participating in a national cohort study—
the Qatar Biobank (QBB)—and who represent the general local population in the State of 
Qatar (31); and iii) 231 pediatric subjects with Qatari nationality who were admitted to, or 
visited outpatient clinics of, Sidra Medicine. Leftover plasma samples from healthy blood bank 
donors were collected from 2012 to 2016, de-identified and stored at -80oC. For the purpose 
of this study, specimen from male Qatari nationals 19 to 66 years of age (Supplementary Table 
S1) were selected from a larger blood donor cohort including 5983 individuals, and then age-
matched male donors with other nationalities were randomly selected (Supplementary Figure 
S1). Samples from female blood bank donors were excluded because they were largely 
underrepresented in the blood bank donor cohort. We also excluded samples for which age, 
gender or nationality information was lacking. Serum samples from the QBB cohort were 
collected from 2012 to 2017 and were randomly selected samples from the first 3000 
individuals taking part in a longitudinal cohort study as described previously (31). Plasma 
samples from pediatric patients were selected from leftovers of samples processed in the 
clinical chemistry labs of Sidra Medicine, a tertiary care hospital for children and women in 
Doha, Qatar, over a period of several months from September to November 2019. In order to 
select appropriate pediatric samples, electronic medical records were queried using Discern 
analytics to identify blood samples from Qatari nationals aged 7 to 15 years for whom basic 
metabolic panel (BMP) and comprehensive metabolic panel (CMP) testing was done in the 
previous week. Samples from oncology patients, patients requiring complex care and those 
in intensive care units, as well as samples from patients with chronic diseases, samples with 
no centile data and samples from patients who were underweight (centile <5%) or overweight 
were excluded. However, we included obese patients in our analysis, since a considerable 
proportion of Qatari nationals are overweight. One of the COVID-19 patient assessed in this 
study was a previously healthy female Belgian national with autosomal recessive IRF7 
deficiency who developed ARDS following SARS-CoV-2 infection at the age of 49 (73). For 
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comparison, we also assessed unexposed family members, including the father, mother, 
brother (heterozygous carriers) and wild-type sister, as well as an unrelated age- and gender-
matched healthy control. Additional male COVID-19 patients assessed in this study were 
between 30 and 68 years of age, residents of the State of Qatar with diverse Nationality 
(Supplementary Table S6). All patients assessed here required intensive care for COVID-19; 
however, information about preexisting comorbidities among the latter patients were not 
obtained.    
 
Phage Immunoprecipitation-Sequencing (PhIP-Seq). The VirScan phage library used for PhIP-
Seq in the present study had been obtained from S. Elledge (Brigham and Women’s Hospital 
and Harvard Medical School, Boston, MA, USA). Large scale serological profiling of the 
antiviral IgG repertoires in the individual serum or plasma samples was performed as 
described by Xu el al. (30). Each serum or plasma sample was tested in duplicate and samples 
were analyzed in batches with up to 96 samples per batch. Only samples that satisfied a 
minimum read count of 1*106 as well as a Pearson correlation coefficient of ³ 0.7 in the two 
technical repeats were considered for downstream analysis. Data from thirty individuals of 
the ABD cohort and two individuals of the QBB cohort were excluded from the downstream 
analysis due to insufficient sequencing read depth, low sequencing data quality or because 
one of two technical replicates had failed (data not shown). 
 
Peptide enrichment analysis. To filter for enriched peptides, we first imputed −log10(P) 
values as described previously (30, 32, 35) by fitting a zero-inflated generalized Poisson model 
to the distribution of output counts and regressed the parameters for each peptide sequence 
based on the input read count. We considered a peptide enriched if it passed a reproducibility 
threshold of 2.3 [−log10(P)] in two technical sample replicates. To remove sporadic hits, we 
then filtered for antibody specificities to CoV peptides that were found to be enriched in at 
least three of all 1399 subjects assayed and analyzed in this study. We computed species-
specific significance cut-off values to estimate minimum number of enriched, non-
homologous peptides required in order to consider a sample as seropositive using a 
generalized linear model and in-house serological (ELISA) data from pooled samples that were 
tested positive for various viruses. We then computed virus score values as described by Xu 
et al (30) by counting enriched, non-homologous peptides for a given species and then 
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adjusted these score values by dividing them with the estimated score cutoff. For the purpose 
of this study, we considered a peptide to be immunodominant if it was enriched in ³ 1% of 
the samples obtained from the three larger cohorts (N = 1399) assayed and analyzed in this 
study. 
 
Association studies and differential enrichment analysis. We applied a generalized linear 
model to test for associations between the HCoV species-specific adjusted score values, 
gender and age. We considered an association to be significant if the P value was £ 0.001. We 
examined the frequency distribution of enriched peptides among samples of the different age 
groups (PED versus ABD + QBB) by estimating OR (reported as lod) and associated P values 
using Fisher’s exact test. Peptides that satisfied both significance (P value £ 0.005) and 
magnitude criteria (|OR|  ³ 2) were considered to be differentially enriched. Positive OR and 
lod values indicated more frequent peptide enrichment among pediatric study subjects, 
whereas negative OR and lod values indicated more frequent peptide enrichment among 
adult subjects. 
 
Clustering of peptides for shared linear B cell epitopes. To estimate the minimum number 
of linear B cell epitopes among the enriched peptides, we built a pairwise distance matrix that 
captured the maximum size of linear sequence identity of amino acids (di,j) between all 
enriched peptides. Groups of peptides that shared ³ seven amino acid linear sequence 
identity (di,j ³ 7) were assigned to a cluster. Peptides of a given cluster were considered to 
share a linear B cell epitope (Supplementary Figure S9). 
 
Software. For statistical analyses and principal component analysis (PCA), we used open 
source Python modules detailed below.  Multiple sequence alignments were done using the 
MAFFT  (74, 75) via EMBL-EBI’s web services and Java Alignment Viewer (Jalview) for 
visualization (76). Network analysis of peptide clusters (Figure 5 and Supplementary Figure 
S9) was performed using Python module NetworkX (version 2.5). Linear B cell epitopes were 




Statistics. All statistical analyses were performed with Python (version 3.6) using open-source 
modules, such as SciPy (version 1.14.1), Scikit-learn (version 0.23), Statsmodels (version 0.11) 
and in-house scripts. Antibody prevalence values for different species (Figure 1A, 
Supplementary Figure S4A and Supplementary Table S5) were determined by dividing the 
number of seropositive individuals of a given group (i.e., cohort, age group or gender) by the 
total number of samples of the respective group; calculated values were reported as 
percentage (%). For differential enrichment analysis of peptides in pediatric versus adult 
subjects (Figure 2B and Table 1), we used Fisher’s exact test and accounted for multiple 
testing by Bonferroni correction. P values < 0.005 were considered statistically significant. For 
association studies (Figure 1B), we used Student’s t-test and Bonferroni correction, and 
considered associations with P values < 0.001 to be statistically significant. 
 
Study approval. The human subject research described here had been approved by the 
institutional research ethics boards of Sidra Medicine, Qatar Biobank, INSERM, Erasme 
Hospital, Hamad Medical Corporation and Qatar University, depending on where subjects 
were recruited and research was carried out. This included the receipt of written informed 
consent from participants. 
 
Data and code availability. All data are available in the manuscript or the supplementary 
materials. Raw PhIP-Seq reads and Python in-house scripts used in this study are readily 
available upon request. The pipeline for processing the PhIP-Seq data has been published 
previously (29).    
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Figure 1. Seroprevalence of endemic HCoVs. A, Dot plot depicting the seroprevalence of the 
four endemic HCoVs among subjects included in the downstream analysis (N = 1399) after 
stratification by cohort. Grey bars depict the mean seroprevalence value for each species, 
error bars depict the SD. QBB, Qatar Biobank cohort; ABD, adult (male) blood bank donors; 
PED, pediatric study subjects. B, Coefficient of association (beta) with 95% confidence interval 
(95% CI) of seroprevalence for each HCoV with either male gender (green), female gender 














Figure 2. Qualitative differences in antibody repertoires between cohorts and age groups. 
A, Principal component analysis of 417 peptides from endemic HCoVs that were found to be 
enriched in at least 3 samples. QBB, Qatar Biobank cohort (n = 798); ABD, adult (male) blood 
bank donors (n = 370); PED, pediatric subjects (n = 231). B, Differential enrichment analysis 
to determine the peptides that are either more or less frequently enriched in children versus 
adults (including subjects of both adult cohorts, namely QBB and ABD). We considered a 
peptide significantly more or less frequently enriched among children if the odds ratio (OR) 
was ³ 2 or £ -2, respectively; and the P value was £ 0.005 (Fisher’s exact test). pp1ab, ORF1ab 
replicase polyprotein; S, spike glycoprotein; M, matrix glycoprotein; N, nucleocapsid protein; 





Figure 3. Antigenic regions and predicted antibody binding sites of the spike (S) protein. A, 
Schematic representation of the S protein of SARS-CoV (UniProtKB entry P59594). Proteolytic 
cleavage sites are marked with arrows. FP, fusion peptide; HR, heptad repeats; TMD, 
transmembrane domain. B, Overview of a multiple sequence alignment of immunodominant 
peptides with the full-length protein sequences of various alpha- and beta-CoVs (top). Row 
labels indicate the UniProtKB sequence identifier, start and end positions of enriched 
peptides (in parentheses), names of the organisms and cluster numbers (in square brackets). 
Peptides for which differential enrichment between children and adults was statistically 
significant (P-value  £ 0.005, Fisher’s exact test) and OR were ³ 2 are indicated with a “*”. 
Colors indicate protein domains as shown in (A), as well as predicted (pink) (42) and 
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indicate boundaries of regions shown in (C), (D) and (E). The line plot (bottom) shows the 
mean BepiPred score (blue line) and SD (shaded) for the prediction of linear B cell epitopes 
among endemic HCoVs. The significance threshold of 0.55 has been marked with a dashed 
red line. C-E, Selected regions of the multiple sequence alignment encompassing the N-
terminal region of the receptor binding domain (C), the S1/S2 cleavage site (D) and the S2’ 
cleavage site (E). Amino acid positions on top are shown for UniProtKB entry P59594. Amino 
acids are marked in color to indicate the level of sequence identity (blue), the proteolytic 
cleavage sites (black) and linear SARS-CoV-2 B cell epitopes as shown in (B). The full sequence 




Figure 4. Antigenic regions and predicted antibody binding sites of the nucleocapsid (N) 
protein. A, Schematic representations of the N protein of SARS-CoV (UniProtKB entry 
P59595). SR-rich, serine- and arginine-rich motive; NLS, Predicted nuclear localization 
sequence; IDR, intrinsically disordered region. B, Overview of a multiple sequence alignment 
of immunodominant peptides with the full-length protein sequences of various alpha- and 
beta-CoVs (top). Row labels indicate the UniProtKB sequence identifier, start and end 
positions of enriched peptides (in parentheses), names of the organisms and cluster numbers 
(in square brackets). Peptides for which differential enrichment between children and adults 
was statistically significant (P-value  £ 0.005, Fisher’s exact test) and OR were ³ 2 are indicated 
with a “*”. Colors indicate protein domains as shown in (A) and predicted linear SARS-CoV-2 
B cell epitopes (pink) (42). Vertical dashed lines indicate boundaries of the regions shown in 
(C) and (D). The line plot (bottom) shows the mean BepiPred score (blue line) and SD (shaded) 
for the prediction of linear B cell epitopes among endemic HCoVs. The significance threshold 
of 0.55 has been marked with a dashed red line. C, D, Selected regions of the multiple 
sequence alignment encompassing the N-terminal RNA-binding domain (C) and C-terminal 
self-assembly domain (D). Amino acid positions on top are shown for UniProtKB reference 
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identity (blue) and linear SARS-CoV-2 B cell epitopes (red). The full multiple sequence 




Figure 5. Network representation of enriched peptides from structural proteins targeted by 
cross-reactive antibodies. A, Network representation of enriched spike (S) protein-derived 
peptides. B, Network representation of enriched nucleoprotein (N)-derived peptides. Each 
node represents an enriched peptide and the color indicates the species. Edges indicate ³ 
seven amino acids linear sequence identity between two nodes (i.e. peptides), the estimated 
size of a linear B cell epitope. Only networks of peptides derived from at least two different 
species are shown. Labels indicate the cluster number to which each peptide has been 
assigned. Nodes are represented as spheres if the peptide had been frequently enriched. 
Nodes marked with a black circle indicate peptides for which differential enrichment between 
children and adults was statistically significant (P value £ 0.005, Fisher’s exact test) and OR 
were ³ 2. SR-rich, serine- and arginine-rich motive; IDR, intrinsically disordered region; *, 

















Table 1. List of peptides that were differentially enriched in children (n = 231) versus 




StartA EndA Protein 
symbol 




Cluster annotationB / peptide location 
P0C6X6 1401 1456 pp1ab HCoV-OC43 6.4 4.7 136 Papain-like proteinase 
Q0ZJJ1 813 868 pp1ab HCoV-HKU1 6.3 3.9 102 Papain-like proteinase 
Q0ZJJ1 225 280 pp1ab HCoV-HKU1 6.0 3.1 38 3C-like proteinase 
P0C6X2 7029 7084 pp1ab HCoV-HKU1 6.0 3.1 117 2'-O-methyltransferase 
Q5MQD0 365 420 S HCoV-HKU1 6.0 3.1 189 S1 chain region 
Q0ZJJ1 5825 5880 pp1ab HCoV-HKU1 5.7 2.4 9 RNA virus helicase 
P0C6X5 3753 3808 pp1ab HCoV-NL63 5.7 2.4 10 Non-structural protein 8 
Q0QJI4 337 392 S HCoV-OC43 5.7 2.4 98 S1/S2 cleavage site 
P0C6X3 5489 5544 pp1ab HCoV-HKU1 4.5 12.3 8 Helicase 
Q6Q1R9 197 226 M HCoV-NL63 3.2 3.2 185 Interaction with N protein region 
P0C6X6 2381 2436 pp1ab HCoV-OC43 3.2 3.2 253 Non-structural protein 3 
Q6Q1S2 421 476 S HCoV-NL63 3.0 2.5 131 S1 chain region 
Q6Q1S2 449 504 S HCoV-NL63 3.0 2.5 131 S1 chain region 
P0C6X1 1373 1428 pp1ab HCoV-229E 3.0 2.5 235 Non-Structural protein 3 
P0C6X2 3305 3360 pp1ab HCoV-HKU1 2.7 5.0 13 Region of 3C-like proteinase 
Q6Q1R8 29 84 N HCoV-NL63 2.5 6.0 49 N-terminal RNA binding domain 
E2DNV6 1 56 N HCoV-NL63 2.2 7.3 37 N-terminal RNA binding domain 
Q6Q1R8 169 224 N HCoV-NL63 1.8 2.4 37 N-terminal RNA binding domain 
Q5SBN5 1 56 N HCoV-NL63 1.8 2.4 49 N-terminal RNA binding domain 
Q6Q1R8 197 252 N HCoV-NL63 1.8 7.8 37 N-terminal RNA binding domain 
Q5MQC5 1 56 ORF8 HCoV-HKU1 1.7 5.9 41 N-terminal RNA binding domain 
Q6Q1R8 337 377 N HCoV-NL63 1.6 24.6 132 C-terminal of dimerization domain 
P0C6X2 5461 5516 pp1ab HCoV-HKU1 1.5 2.8 34 RNA virus helicase C-terminal 
P0C6X5 4285 4340 pp1ab HCoV-NL63 1.5 2.5 78 RNA-directed RNA polymerase 
E2DNV6 29 84 N HCoV-NL63 1.5 8.5 37 N-terminal RNA binding domain 
Q5SBN5 29 83 N HCoV-NL63 1.5 3.2 49 N-terminal RNA binding domain 
Q0ZJJ1 1121 1176 pp1ab HCoV-HKU1 1.4 4.6 12 Asp-rich region, Papain-like proteinase 
P15423 645 700 S HCoV-229E 1.3 2.8 16 Furin-like S2’ cleavage site 
G9G2X4 1 56 N HCoV-HKU1 1.2 5.3 41 N-terminal RNA binding domain 
Q01455 197 230 M HCoV-OC43 1.2 3.5 147 Interaction with N protein region 
Q6Q1R8 309 364 N HCoV-NL63 1.1 9.5 132 C-terminus of dimerization domain 
P0C6X2 4509 4564 pp1ab HCoV-HKU1 1.1 3.6 2 RNA-directed RNA polymerase 
Q0QJI4 757 812 S HCoV-OC43 1.0 4.9 46 Receptor binding domain 
Q5MQC5 29 84 ORF8 HCoV-HKU1 1.0 3.0 41 N-terminal RNA-binding domain 
P0C6X2 1065 1120 pp1ab HCoV-HKU1 0.9 2.8 12 Asp-rich region, Papain-like proteinase 
P0C6X1 5377 5432 pp1ab HCoV-229E -2.2 2.4 9 RNA virus helicase 
Q0ZJJ1 965 1020 pp1ab HCoV-HKU1 -2.7 26.8 12 Asp-rich region, Papain-like proteinase 
P0C6X4 897 952 pp1ab HCoV-HKU1 -3.0 6.5 12 Asp-rich region, Papain-like proteinase 
Q0ZJG7 925 980 pp1ab HCoV-HKU1 -3.4 40.7 12 Asp-rich region, Papain-like proteinase 
P0C6X4 925 980 pp1ab HCoV-HKU1 -3.6 65.2 12 Asp-rich region, Papain-like proteinase 
P0C6X3 925 980 pp1ab HCoV-HKU1 -3.6 65.4 12 Asp-rich region, Papain-like proteinase 
P0C6X4 953 1008 pp1ab HCoV-HKU1 -4.0 81.9 12 Asp-rich region, Papain-like proteinase 
P0C6X2 1037 1092 pp1ab HCoV-HKU1 -4.0 66.6 12 Asp-rich region, Papain-like proteinase 
P0C6X4 1009 1064 pp1ab HCoV-HKU1 -4.1 89.8 12 Asp-rich region, Papain-like proteinase 
Q0ZJJ1 1037 1092 pp1ab HCoV-HKU1 -4.2 106.1 12 Asp-rich region, Papain-like proteinase 
P0C6X3 1009 1064 pp1ab HCoV-HKU1 -4.3 94.1 12 Asp-rich region, Papain-like proteinase 
P0C6X2 951 1006 pp1ab HCoV-HKU1 -4.3 114.6 12 Asp-rich region, Papain-like proteinase 
P0C6X3 1037 1092 pp1ab HCoV-HKU1 -4.4 105.0 12 Asp-rich region, Papain-like proteinase 
P0C6X4 981 1036 pp1ab HCoV-HKU1 -4.9 139.5 12 Asp-rich region, Papain-like proteinase 
P0C6X2 925 980 pp1ab HCoV-HKU1 -5.2 147.1 12 Asp-rich region, Papain-like proteinase 
Q0ZJJ1 925 980 pp1ab HCoV-HKU1 -5.3 153.3 12 Asp-rich region, Papain-like proteinase 
P0C6X3 953 1008 pp1ab HCoV-HKU1 -5.5 162.7 12 Asp-rich region, Papain-like proteinase 
P0C6X3 951 1006 pp1ab HCoV-HKU1 -5.9 183.5 12 Asp-rich region, Papain-like proteinase 
Q0ZJJ1 1093 1148 pp1ab HCoV-HKU1 -6.0 182.1 12 Asp-rich region, Papain-like proteinase 
P0C6X2 949 1004 pp1ab HCoV-HKU1 -6.2 192.8 12 Asp-rich region, Papain-like proteinase 
Q0ZJJ1 953 1008 pp1ab HCoV-HKU1 -6.2 190.9 12 Asp-rich region, Papain-like proteinase 
P0C6X2 953 1008 pp1ab HCoV-HKU1 -6.2 195.5 12 Asp-rich region, Papain-like proteinase 
Q0ZJJ1 979 1034 pp1ab HCoV-HKU1 -6.6 204.6 12 Asp-rich region, Papain-like proteinase 
P0C6X4 4761 4816 pp1ab HCoV-HKU1 -7.1 21.0 36 RNA-directed RNA polymerase 
Q0ZJG7 4985 5040 pp1ab HCoV-HKU1 -8.1 47.6 21 3C-like proteinase 
P0C6X1 337 392 pp1ab HCoV-229E -9.8 128.6 219 Non-structural protein 2 
 
AStart and end position of enriched peptides relative to the amino acid sequences in 
UniProtKB. BCluster annotation was adapted from UniProtKB entry descriptions and 
features. Only peptides with a log odds ratio (lod) ³ ln(2) or ≤ ln(-2) and a P value < 0.005 
(Fisher’s exact test) are listed. Immunodominant peptides (i.e., peptides found to be 
significantly enriched in ³1% of samples of the tested individuals (N = 1399)) are marked in 
bold font. 
